Improved influenza vaccines: full value vaccine assessment

Seasonal influenza remains a major global public health challenge, causing substantial morbidity and mortality each year. The World Health Organization (WHO) conducted the Full Value of Improved Influenza Vaccine Assessment (FVIVA) to evaluate the health, economic, and policy impacts of next-generation influenza vaccines and identify barriers to their uptake.

The FVIVA examines the vaccine development pipeline, quantifies projected health and economic benefits, assesses financial viability for manufacturers, and identifies country preferences and implementation challenges. It provides a basis to guide investment, policy decisions, and introduction strategies – supporting stronger seasonal programs and enhanced pandemic preparedness.

Auteurs